中国医学创新2019，Vol.16Issue(2)：62-66,5.DOI:10.3969/j.issn.1674-4985.2019.02.016
重组人脑利钠肽治疗急性心力衰竭的临床研究
Clinical Research of Recombinant Human Brain Natfiuretic Peptide in the Treatment of Acute Heart Failure
摘要
Abstract
Objective:To discussing the clinical efficacy of Recombinant Human Brain Natfiuretic Peptide in the treatment of acute heart failure.Method:100 patients with acute heart failure were selected in our hospitals from January 2016 to December 2017 were selected, they were divided into observation group and control group, according to the random number table method, 50 cases in each group.The observation group was treated with Recombinant Human Brain Natriuretic Peptide and the control group was treated with Nitroglycerin.The changes of hemodynamic parameters, vital signs parameters, biochemical indexes, respiratory difficulties and systemic clinical status scores before and after administration of the two groups were observed, and the adverse reactions and adverse cardiovascular events of patients during the whole process of administration were observed.Result:Before drug administration, there were no statistically significant differences in hemodynamic parameters, vital signs, biochemical indexes, respiratory difficulties and systemic clinical conditions between the two groups (P＞0.05).PCWP and PAP in the observation group were significantly lower than those in the control group, 30 min, 1, 2 and 24 h after administration (P＜0.05).24 h after administration, the 24 h urine volume, respiratory difficulty and systemic clinical status score of the observation group were significantly higher than those of the control group, the differences were statistically significant (P＜0.05).24 h after administration, there were no statistically significant differences in K+ and Scr between the two groups (P＞0.05), but BNP of the observation group was significantly lower than that of the control group (P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion:Recombinant Human Brain Natriuretic Peptide can effectively treat acute heart failure, and is worthy of clinical application.关键词
重组人脑利钠肽/急性心力衰竭/血流动力学Key words
Recombinant Human Brain Natfiuretic Peptide/Acute heart failure/Hemodynamics引用本文复制引用
陈天海,刘凯东,徐启明..重组人脑利钠肽治疗急性心力衰竭的临床研究[J].中国医学创新,2019,16(2):62-66,5.基金项目
佛山市卫生局医学科研课题立项(2014170) （2014170）
